泰和科技 reported revenue of ¥1.37B for the period ended 2026-06-30, -1.4% year on year. Net income was ¥0.14B, a 10.2% net margin on a 19.4% gross margin. The largest revenue line is 水处理药剂及其联副产品 at 81% of the total. Free cash flow for the period was ¥0.18B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.37B | -1.4% |
| Gross profit | ¥0.27B | — |
| Operating income | ¥0.17B | — |
| Net income | ¥0.14B | +148.2% |
| Gross margin | 19.4% | Net margin 10.2% |
| Revenue Q/Q | -12.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 水处理药剂及其联副产品 | ¥1.11B | 80.8% |
| 氯碱产品 | ¥0.25B | 18.2% |
| 其他(补充) | ¥0.01B | 1.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.11B | 80.6% |
| R&D | ¥0.03B | 2.2% |
| SG&A | ¥0.06B | 4.2% |
| Tax & other | ¥0.03B | 1.9% |
| Item | Amount |
|---|---|
| Total assets | ¥3.14B |
| Total liabilities | ¥0.47B |
| Shareholders' equity | ¥2.67B |
| Equity / assets | 84.9% |
| Operating cash flow | ¥0.18B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.18B |
| Cash conversion (OCF / net income) | 125% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
矩子科技 ・ 广康生化 ・ 电声股份 ・ 斯迪克 ・ 天迈科技 ・ 久量股份 ・ 华辰装备 ・ 中科海讯 ・ 铂科新材 ・ 易天股份 ・ 泰林生物 ・ 中富电路
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies